The Board of Directors of Lixte Biotechnology Holdings, Inc. appointed Bastiaan van der Baan to the Board as an independent director, effective as of June 17, 2022. Mr. van der Baan has over twenty years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization, as well as the establishment of partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies and governments to successfully launch new oncology products.